Invested in
Invivyd?
Attention Invivyd shareholders: contact investor lawyers for a free evaluation of your potential claims for compensation today.
- Did you invest in or otherwise acquired shares in Invivyd, Inc. (NASDAQ: IVVD), formerly known as Adagio Therapeutics, in or before November 2021 and still hold them?
- Are you concerned about the IVVD stock price decline following alleged misrepresentations regarding the effectiveness of Invivyd’s lead product candidate ADG20 against the Omicron variant of COVID-19?
- Would you like your potential options for compensation and/or redress to be reviewed by an experienced team of investor lawyers?
Request a free case evaluation of your potential claims for compensation today, via email at arosca@rscounsel.law, through the contact form on this page, or by calling 888-998-0530.
Contact Us About Your
Investments
Free Case Evaluation
The Invivyd Class Action Investigation page is the resource for investors who bought Invivyd fka Adagio Therapeutics shares in or before November 2021 and would like to evaluate compensation claims.
- Free Case Evaluation
- No Fees if No Recovery
- Contact Us Today
We can also do a Zoom call to discuss your matter.
Posted May 1, 2023
Invivyd Investigation
Securities attorneys Alan Rosca, Paul Scarlato, and Kathryn Weidner have been investigating alleged securities violations, corporate misconduct, and misrepresentations, as well as questionable business practices involving Invivyd, Inc., and have identified potential areas of concern for Invivyd investors.
What Invivyd Investors May Do
IVVD investors interested in evaluating potential options to seek compensation and/or pursue claims related to their Invivyd investment may contact investor rights attorneys Alan Rosca, Paul Scarlato, or Kathryn Weidner. Claims that are not timely pursued may expire or otherwise be lost, generally speaking.
Get in Touch with an Experienced Team of Investor Attorneys
Attorneys Rosca, Scarlato, and Weidner have extensive experience in seeking compensation related to investor harm and pursuing claims arising out of alleged violations of securities law and/or corporate misconduct, and are currently evaluating potential claims on behalf of investors in Invivyd, Inc.
They typically work on a contingent fee basis, do not require any money down from their clients, advance case expenses, and only get paid for their fees and expenses if and when successful, following review and approval by the Court of any fee application.
Concerned IVVD stock investors may contact attorneys Alan Rosca, Paul Scarlato, or Kathryn Weidner to discuss their potential options toll free at 888-998-0530, via email at arosca@rscounsel.law, or through the contact form on this webpage.
Potential Compensation Claims
Has Invivyd fka Adagio Therapeutics Been Accused of Misconduct?
Invivyd, Inc., and its co-founders Tillman U. Gerngross, and Laura Walker, have been the subject of a class action lawsuit, filed in the United States District Court for the District of Massachusetts in January 2023.
Invivyd and its control persons were accused in that class action lawsuit of, among others, violating securities laws by allegedly making materially false and/or misleading statements and failing to disclose material adverse facts that allegedly caused Invivyd’s stock to trade at artificially inflated prices.
The complaint alleged that contrary to representations made to investors, Invivyd’s investigational monoclonal antibody treatment for COVID-19 called ADG20 was 300 times less effective at neutralizing Omicron than it was against the other variants. The press release dated December 14, 2021 quotes Adagio Therapeutics’ CEO Tillman Gerngross declaring that “new data show that the combination of mutations present in the Omicron spike protein led to a reduction in ADG20 neutralization that was not suggested by prior data,” which contrasts his earlier statement just a few weeks earlier when he reportedly stated that ADG20 “will neutralize SARS-CoV-2 and all its known variants.” Following the news, the Invivyd stock reportedly lost over 80% of its value, plummeting from $34.26 to just above $6 per share by December 15, 2021.
According to data provided by Yahoo Finance, on April 27, 2023, the price per IVVD share was $1.12.
What Happened to Adagio’s/Invivyd’s CEO and directors?
In mid-February 2022, Tillman Gerngross reportedly announced his agreement in principle to resign from his position as Adagio Therapeutics’ CEO. Shortly after, on February 23, 2022, the company announced the departure of its Chief Medical Officer, Lynn Connolly.
In June 2022 additional resignations were announced by two former members of board of directors, Anand Shah and Howard Mayer.
Another director, Redonda Miller, announced her resignation from Invivyd’s board of directors on October 20, 2022, which was just a few days after Jane Henderson, the Company’s Chief Financial & Business Officer, announced her separation from the company.
Do Invivyd Shareholders Have Claims for Compensation, Corporate Reform and/or Other Redress?
Investor rights attorneys Alan Rosca, Paul Scarlato, and Kathryn Weidner at Rosca Scarlato are investigating potential options and are evaluating potential claims for compensation on behalf of IVVD shareholders. They have decades of combined experience representing victims of corporate or financial misconduct.
If you are a Invivyd investor concerned about your investment and/or its value, you may contact attorneys Alan Rosca, Paul Scarlato, or Kathryn Weidner to learn more about your rights and for an evaluation of your potential claims, or to provide useful information.
All consultations are free. The Rosca Scarlato attorneys typically take cases like this on a contingency fee basis, advance all case costs, and only get paid for their fees and expenses if and when they are successful, following review and approval by the Court of any fee application.
To reach attorney Alan Rosca or his colleagues, Invivyd investors may call 888-998-0530, email arosca@rscounsel.law, or leave a message through the contact form on this webpage.
The general considerations on this page are for informational purposes only and do not constitute legal advice. Such legal advice can only be offered once the attorneys discuss each investor’s situation, learn of the relevant facts and can tailor any advice to that investor’s facts. The Invivyd Class Action Investigation page is not affiliated with Invivyd, Inc. There has not been an adjudication on the merits of the cases referenced in this blog post, as of the date of the posting.
Contact info:
Rosca Scarlato LLC – 216-946-7070 / 888-998-0530.
Alan Rosca – arosca@rscounsel.law
Paul Scarlato – pscarlato@rscounsel.law
Kathryn Weidner – kweidner@rscounsel.law
Recent Investigations
DISCLAIMER
In our legal system, every person is innocent until and unless found guilty by a court of law or a tribunal. Whenever we reference “allegations” or charges that are “alleged,” such allegations or charges have not been proven, and are merely accusations, not findings of fault, as of the date of the blog. We do not have, nor do we undertake, a duty to continue to monitor or follow matters about which we report, and/or to publish subsequent updates regarding various developments that may occur in such matters. Readers are encouraged to conduct their own research regarding any such matters and any developments that may or may not have occurred in such matters. Also, the Brokercheck report linked to some of our blogs is the up-to-date version as of the date of accessing by the reader. The information in our blogs is current as of the date of the drafting of the blog, and given that sometimes certain past complaints may no longer be listed in newer Brokercheck reports, some of the events referenced in some of our blogs may later on be removed from newer Brokercheck reports. Visitors may check the most recent version of each brokercheck report at www.finra.org, and may contact FINRA for the earlier version of the Brokercheck report upon which various blogs may be based.
